This is a randomized, double blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose) as treatment for heart failure with iron deficiency. Study drug administration will occur as two intravenous doses every six months for duration of study.
CRITERIA LIST/ QUALIFICATIONS:
Stable heart failure with ejection fraction ≤35%
Able and willing to perform a walk test
Willing and able to come to the study site for infusions every 6 months for about 4 years